Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation

Frontiers in Endocrinology

Volumn 6, Issue APR, 2015, Pages

  Farabaugh, Susan M ^a,b   Boone, David N ^a,b   Lee, Adrian V ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breast cancer subtypes; ER+; ERBB2+; IGF1R; Lineages; Luminal; Triple negative

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FIGITUMUMAB; G PROTEIN COUPLED RECEPTOR 30; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; NAVELBINE; OCTAMER TRANSCRIPTION FACTOR 4; PROGESTERONE RECEPTOR; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; UNINDEXED DRUG;

AUTOPHOSPHORYLATION; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL COMPOSITION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; HOMEOSTASIS; HUMAN; MAMMARY GLAND FUNCTION; MORPHOGENESIS; NONHUMAN; ONCOGENE C MYC; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TRIPLE NEGATIVE BREAST CANCER;

EID: 84930661622     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00059     Document Type: Review

References (163)

1. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev (1994) 15:80-101. doi: 10.1210/edrv-15-1-80.
2. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science (2003) 299:1346-51. doi:10.1126/science.1081447.
3. Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R, et al. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat (1998) 52:175-84. doi:10.1023/A:1006127621512.
4. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol (2002) 3:298-302. doi:10.1016/S1470-2045(02)00731-3.
5. Munshi S, Hall DL, Kornienko M, Darke PL, Kuo LC. Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution. Acta Crystallogr D Biol Crystallogr (2003) 59:1725-30. doi:10.1107/S0907444903015415.
6. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 14:6364-70. doi:10.1158/1078-0432.CCR-07-4879.
7. Danielsen A, Larsen E, Gammeltoft S. Chromaffin cells express two types of insulin-like growth factor receptors. Brain Res (1990) 518:95-100. doi:10.1016/0006-8993(90)90958-E.
8. Moxham CP, Duronio V, Jacobs S. Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem (1989) 264:13238-44.
9. Soos MA, Siddle K. Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. Biochem J (1989) 263:553-63.
10. Treadway JL, Morrison BD, Goldfine ID, Pessin JE. Assembly of insulin/insulin-like growth factor-1 hybrid receptors in vitro. J Biol Chem (1989) 264:21450-3.
11. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res (1999) 5:1935-44.
12. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem (2002) 277:39684-95. doi:10.1074/jbc. M202766200.
13. Boone DN, Lee AV. Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog (2012) 17:161-73. doi:10.1615/CritRevOncog.v17.i2.30.
14. Myers MG Jr, Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Backer JM, et al. IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. Endocrinology (1993) 132:1421-30. doi:10.1210/endo.132.4.8384986.
15. Dearth RK, Cui X, Kim HJ, Kuiatse I, Lawrence NA, Zhang X, et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 26:9302-14. doi:10.1128/MCB.00260-06.
16. Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle (2004) 3:372-9. doi:10.4161/cc.3.2.624.
17. Peruzzi F, Prisco M, Morrione A, Valentinis B, Baserga R. Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4. J Biol Chem (2001) 276:25990-6. doi:10.1074/jbc. M103188200.
18. Buchwalter G, Gross C, Wasylyk B. Ets ternary complex transcription factors. Gene (2004) 324:1-14. doi:10.1016/j.gene.2003.09.028.
19. Mittelstadt PR, Salvador JM, Fornace AJ Jr, Ashwell JD. Activating p38 MAPK: new tricks for an old kinase. Cell Cycle (2005) 4:1189-92. doi:10.4161/cc.4.9.2043.
20. Sunami T, Byrne N, Diehl RE, Funabashi K, Hall DL, Ikuta M, et al. Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation. J Biol Chem (2010) 285:4587-94. doi:10.1074/jbc. M109.040667.
21. Mahmoudabady M, Mathieu M, Touihri K, Hadad I, Da Costa AM, Naeije R, et al. Cardiac insulin-like growth factor-1 and cyclins gene expression in canine models of ischemic or overpacing cardiomyopathy. BMC Cardiovasc Disord (2009) 9:49. doi:10.1186/1471-2261-9-49.
22. Tognon CE, Sorensen PH. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets (2012) 16:33-48. doi:10.1517/14728222.2011.638626.
23. Kleinberg DL, Ruan W, Catanese V, Newman CB, Feldman M. Non-lactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland. Endocrinology (1990) 126:3274-6. doi:10.1210/endo-126-6-3274.
24. Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology (1995) 136:1296-302. doi:10.1210/endo.136.3.7867584.
25. Walden PD, Ruan W, Feldman M, Kleinberg DL. Evidence that the mammary fat pad mediates the action of growth hormone in mammary gland development. Endocrinology (1998) 139:659-62. doi:10.1210/endo.139.2.5718.
26. Ruan W, Kleinberg DL. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology (1999) 140:5075-81. doi:10.1210/endo.140.11.7095.
27. Richards RG, Klotz DM, Walker MP, Diaugustine RP. Mammary gland branching morphogenesis is diminished in mice with a deficiency of insulin-like growth factor-I (IGF-I), but not in mice with a liver-specific deletion of IGF-I. Endocrinology (2004) 145:3106-10. doi:10.1210/en.2003-1112.
28. Bonnette SG, Hadsell DL. Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology (2001) 142:4937-45. doi:10.1210/endo.142.11.8500.
29. Hadsell DL, Bonnette SG, Lee AV. Genetic manipulation of the IGF-I axis to regulate mammary gland development and function. J Dairy Sci (2002) 85:365-77. doi:10.3168/jds. S0022-0302(02)74083-6.
30. Lee AV, Zhang P, Ivanova M, Bonnette S, Oesterreich S, Rosen JM, et al. Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland. Endocrinology (2003) 144:2683-94. doi:10.1210/en.2002-221103.
31. Stull MA, Rowzee AM, Loladze AV, Wood TL. Growth factor regulation of cell cycle progression in mammary epithelial cells. J Mammary Gland Biol Neoplasia (2004) 9:15-26. doi:10.1023/B:JOMG.0000023585.95430.f4.
32. Kleinberg DL, Ruan W. IGF-I, GH, and sex steroid effects in normal mammary gland development. J Mammary Gland Biol Neoplasia (2008) 13:353-60. doi:10.1007/s10911-008-9103-7.
33. Scott J, Cowell J, Robertson ME, Priestley LM, Wadey R, Hopkins B, et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature (1985) 317:260-2. doi:10.1038/317260a0.
34. Wu HK, Squire JA, Catzavelos CG, Weksberg R. Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun (1997) 235:123-9. doi:10.1006/bbrc.1997.6744.
35. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 279:563-6. doi:10.1126/science.279.5350.563.
36. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 351:1393-6. doi:10.1016/S0140-6736(97)10384-1.
37. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 363:1346-53. doi:10.1016/S0140-6736(04)16044-3.
38. Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer (2004) 111:418-23. doi:10.1002/ijc.20233.
39. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K. Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature. Int J Cancer (2004) 111:293-7. doi:10.1002/ijc.20253.
40. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst (2000) 92:1472-89. doi:10.1093/jnci/92.18.1472.
41. Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology (2011) 152:2546-51. doi:10.1210/en.2011-0231.
42. TCGA. Comprehensive molecular portraits of human breast tumors. Nature (2012) 490:61-70. doi:10.1038/nature11412.
43. Yu H, Li BD, Smith M, Shi R, Berkel HJ, Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Res Treat (2001) 70:117-22. doi:10.1023/A:1012947027213.
44. Wagner K, Hemminki K, Israelsson E, Grzybowska E, Soderberg M, Pamula J, et al. Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer. Breast Cancer Res Treat (2005) 92:133-40. doi:10.1007/s10549-005-2417-x.
45. Deming SL, Ren Z, Wen W, Shu XO, Cai Q, Gao YT, et al. Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat (2007) 104:309-19. doi:10.1007/s10549-006-9420-8.
46. Tsuchiya N, Wang L, Horikawa Y, Inoue T, Kakinuma H, Matsuura S, et al. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. Int J Oncol (2005) 26:225-31. doi:10.3892/ijo.26.1.225.
47. Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, Kolonel LN, et al. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst (2006) 98:123-34. doi:10.1093/jnci/djj013.
48. Habuchi T. Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model. Future Oncol (2006) 2:233-45. doi:10.2217/14796694.2.2.233.
49. Moon JW, Chang YS, Ahn CW, Yoo KN, Shin JH, Kong JH, et al. Promoter-202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk. Int J Cancer (2006) 118:353-6. doi:10.1002/ijc.21339.
50. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology (2010) 139:464-73.e1-3. doi:10.1053/j.gastro.2010.04.042.
51. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res (2004) 64:286-91. doi:10.1158/0008-5472.CAN-03-1242.
52. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 68:10238-46. doi:10.1158/0008-5472.CAN-08-2755.
53. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 26:4078-85. doi:10.1200/JCO.2007.13.4429.
54. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 98:10869-74. doi:10.1073/pnas.191367098.
55. Kittaneh M, Montero AJ, Gluck S. Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 5:61-70. doi:10.4137/BIC.S9455.
56. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev (2012) 38:698-707. doi:10.1016/j.ctrv.2011.11.005.
57. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 13:787-96. doi:10.1210/mend.13.5.0274.
58. Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S, Surmacz E. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer (1999) 81:299-304. doi:10.1002/(SICI)1097-0215(19990412)81:2<299::AID-IJC21>3.3.CO;2-#.
59. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, et al. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol (2006) 191:605-12. doi:10.1677/joe.1.07016.
60. Bhargava R, Beriwal S, McManus K, Dabbs DJ. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma. Appl Immunohistochem Mol Morphol (2011) 19:218-25. doi:10.1097/PAI.0b013e3181ffc58c.
61. Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, et al. Apoptosis-, proliferation, immune function-, and drug resistance-related genes in ER positive, HER2 positive and triple negative breast cancer. Neoplasma (2012) 59:424-32. doi:10.4149/neo_2012_055.
62. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, et al. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat (2012) 132:131-42. doi:10.1007/s10549-011-1529-8.
63. Shin SJ, Gong G, Lee HJ, Kang J, Bae YK, Lee A, et al. Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer. J Breast Cancer (2014) 17:113-20. doi:10.4048/jbc.2014.17.2.113.
64. Hawsawi Y, El-Gendy R, Twelves C, Speirs V, Beattie J. Insulin-like growth factor-oestradiol crosstalk and mammary gland tumourigenesis. Biochim Biophys Acta (2013) 1836:345-53. doi:10.1016/j.bbcan.2013.10.005.
65. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol (2011) 25:516-28. doi:10.1210/me.2010-0373.
66. Aaltonen KE, Rosendahl AH, Olsson H, Malmstrom P, Hartman L, Ferno M. Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer. BMC Cancer (2014) 14:794. doi:10.1186/1471-2407-14-794.
67. Zhang Y, Moerkens M, Ramaiahgari S, De Bont H, Price L, Meerman J, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res (2011) 13:R52. doi:10.1186/bcr2883.
68. Baxi SM, Tan W, Murphy ST, Smeal T, Yin MJ. Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One (2012) 7:e48402. doi:10.1371/journal.pone.0048402.
69. Miller TW. Endocrine resistance: what do we know? Am Soc Clin Oncol Educ Book (2013). doi:10.1200/EdBook_AM.2013.33.e37.
70. Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, De Boer RH, Jacot W, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, Phase 2 trial. Lancet Oncol (2013) 14:228-35. doi:10.1016/S1470-2045(13)70026-3.
71. Brockdorff BL, Heiberg I, Lykkesfeldt AE. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha. Endocr Relat Cancer (2003) 10:579-90. doi:10.1677/erc.0.0100579.
72. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology (2005) 146:4609-18. doi:10.1210/en.2005-0247.
73. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res (2008) 68:826-33. doi:10.1158/0008-5472.CAN-07-2707.
74. Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, et al. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol (2014) 25:605-10. doi:10.1093/annonc/mdt575.
75. Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res (2012) 72:3372-80. doi:10.1158/0008-5472.CAN-12-0684.
76. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, et al. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res Treat (2010) 123:51-8. doi:10.1007/s10549-009-0631-7.
77. De Marco P, Bartella V, Vivacqua A, Lappano R, Santolla MF, Morcavallo A, et al. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene (2013) 32:678-88. doi:10.1038/onc.2012.97.
78. De Marco P, Romeo E, Vivacqua A, Malaguarnera R, Abonante S, Romeo F, et al. GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocr Relat Cancer (2014) 21:739-53. doi:10.1530/ERC-14-0245.
79. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, et al. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat (2011) 128:457-66. doi:10.1007/s10549-011-1584-1.
80. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat (2010) 123:87-96. doi:10.1007/s10549-009-0624-6.
81. Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G, et al. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res (2013) 15:R114. doi:10.1186/bcr3581.
82. Sjostrom M, Hartman L, Grabau D, Fornander T, Malmstrom P, Nordenskjold B, et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Res Treat (2014) 145:61-71. doi:10.1007/s10549-014-2936-4.
83. Shang Y, Mao Y, Batson J, Scales SJ, Phillips G, Lackner MR, et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther (2008) 7:2599-608. doi:10.1158/1535-7163.MCT-07-2401.
84. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 66:1500-8. doi:10.1158/0008-5472.CAN-05-2925.
85. Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res (2013) 15:R55. doi:10.1186/bcr3449.
86. Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, et al. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Breast Cancer Res Treat (2012) 136:717-27. doi:10.1007/s10549-012-2260-9.
87. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 13:1198-207. doi:10.1158/1078-0432.CCR-06-1304.
88. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS. The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer (2004) 91:1190-4. doi:10.1038/sj.bjc.6602090.
89. Kostler WJ, Hudelist G, Rabitsch W, Czerwenka K, Muller R, Singer CF, et al. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer. J Cancer Res Clin Oncol (2006) 132:9-18. doi:10.1007/s00432-005-0038-8.
90. Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res (2006) 66:7245-52. doi:10.1158/0008-5472.CAN-05-3555.
91. Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Perez-Martinez MC, Cufi S, Del Barco S, et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (herceptin). Int J Oncol (2010) 37:669-78. doi:10.3892/ijo_00000716.
92. Nahta R. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract (2012) 2012:648965. doi:10.1155/2012/648965.
93. Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, et al. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer (2014) 13:71. doi:10.1186/1476-4598-13-71.
94. Ye XM, Zhu HY, Bai WD, Wang T, Wang L, Chen Y, et al. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer (2014) 14:134. doi:10.1186/1471-2407-14-134.
95. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res (2005) 65:11118-28. doi:10.1158/0008-5472.CAN-04-3841.
96. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to herceptin. Cancer Res (2010) 70:1204-14. doi:10.1158/0008-5472.CAN-09-3321.
97. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle (2011) 10:2959-66. doi:10.4161/cc.10.17.16359.
98. Sanabria-Figueroa E, Donnelly S, Foy K, Buss M, Castellino RC, Paplomata E, et al. Insulin-like growth factor-1 receptor signaling increases the invasive potential of HER2-overexpressing breast cancer cells via Src-FAK and FoxM1. Mol Pharmacol (2015) 87(2):150-61. doi:10.1124/mol.114.095380.
99. Chen C, Zhang Y, Li J, Tsao SW, Zhang MY. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Mol Cancer Ther (2014) 13:90-100. doi:10.1158/1535-7163.MCT-13-0558.
100. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2007) 26:2126-32. doi:10.1038/sj.onc.1210014.
101. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 295:2492-502. doi:10.1001/jama.295.21.2492.
102. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 11:R18. doi:10.1186/bcr2242.
103. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol (2012) 23(Suppl 6):vi7-12. doi:10.1093/annonc/mds187.
104. Kalla Singh S, Tan QW, Brito C, De Leon M, De Leon D. Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women. Growth Horm IGF Res (2010) 20:245-54. doi:10.1016/j.ghir.2010.03.001.
105. Hartog H, Horlings HM, Van Der Vegt B, Kreike B, Ajouaou A, Van De Vijver MJ, et al. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat (2011) 129:725-36. doi:10.1007/s10549-010-1256-6.
106. Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res (2011) 17:2314-27. doi:10.1158/1078-0432.CCR-10-1903.
107. Davison Z, De Blacquiere GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia (2011) 13:504-15. doi:10.1593/neo.101590.
108. Rota LM, Albanito L, Shin ME, Goyeneche CL, Shushanov S, Gallagher EJ, et al. IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer Res (2014) 74:5668-79. doi:10.1158/0008-5472.CAN-14-0970.
109. Mancini M, Gariboldi MB, Taiana E, Bonzi MC, Craparotta I, Pagin M, et al. Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. Br J Cancer (2014) 110:2865-73. doi:10.1038/bjc.2014.269.
110. Girgert R, Emons G, Grundker C. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat (2012) 134:199-205. doi:10.1007/s10549-012-1968-x.
111. Steiman J, Peralta EA, Louis S, Kamel O. Biology of the estrogen receptor, GPR30, in triple negative breast cancer. Am J Surg (2013) 206:698-703. doi:10.1016/j.amjsurg.2013.07.014.
112. Abramovitch S, Glaser T, Ouchi T, Werner H. BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett (2003) 541:149-54. doi:10.1016/S0014-5793(03)00315-6.
113. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, et al. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett (2007) 257:236-43. doi:10.1016/j.canlet.2007.07.019.
114. Abramovitch S, Werner H. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene. Horm Metab Res (2003) 35:758-62. doi:10.1055/s-2004-814154.
115. Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer (2007) 14:1053-62. doi:10.1677/ERC-06-0075.
116. Kang HJ, Yi YW, Kim HJ, Hong YB, Seong YS, Bae I. BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site. Cell Death Dis (2012) 3:e336. doi:10.1038/cddis.2012.78.
117. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature (2007) 448:1015-21. doi:10.1038/nature06027.
118. Ziegler AN, Chidambaram S, Forbes BE, Wood TL, Levison SW. Insulin-like growth factor-II (IGF-II) and IGF-II analogs with enhanced insulin receptor-a binding affinity promote neural stem cell expansion. J Biol Chem (2014) 289:4626-33. doi:10.1074/jbc. M113.537597.
119. Musaro A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A (2004) 101:1206-10. doi:10.1073/pnas.0303792101.
120. Mourkioti F, Rosenthal N. IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol (2005) 26:535-42. doi:10.1016/j.it.2005.08.002.
121. Savarese TM, Strohsnitter WC, Low HP, Liu Q, Baik I, Okulicz W, et al. Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. Breast Cancer Res (2007) 9:R29. doi:10.1186/bcr1674.
122. Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne) (2014) 5:10. doi:10.3389/fendo.2014.00010.
123. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 133:704-15. doi:10.1016/j.cell.2008.03.027.
124. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci U S A (2000) 97:12103-8. doi:10.1073/pnas.210394297.
125. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C, et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene (2001) 20:252-9. doi:10.1038/sj.onc.1204064.
126. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer (2010) 10:238. doi:10.1186/1471-2407-10-238.
127. Ye P, Hu Q, Liu H, Yan Y, D'Ercole AJ. Beta-catenin mediates insulin-like growth factor-I actions to promote cyclin D1 mRNA expression, cell proliferation and survival in oligodendroglial cultures. Glia (2010) 58:1031-41. doi:10.1002/glia.20984.
128. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene (2010) 29:2488-98. doi:10.1038/onc.2010.7.
129. Hsu HJ, Drummond-Barbosa D. Insulin signals control the competence of the Drosophila female germline stem cell niche to respond to Notch ligands. Dev Biol (2011) 350:290-300. doi:10.1016/j.ydbio.2010.11.032.
130. Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 208:1809-22. doi:10.1084/jem.20110121.
131. Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene (2004) 23:6156-62. doi:10.1038/sj.onc.1207818.
132. Fernandez C, Tatard VM, Bertrand N, Dahmane N. Differential modulation of Sonic-hedgehog-induced cerebellar granule cell precursor proliferation by the IGF signaling network. Dev Neurosci (2010) 32:59-70. doi:10.1159/000274458.
133. Foti D, Iuliano R, Chiefari E, Brunetti A. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Mol Cell Biol (2003) 23:2720-32. doi:10.1128/MCB.23.8.2720-2732.2003.
134. Werner H, Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol Metab (2006) 17:236-42. doi:10.1016/j.tem.2006.06.007.
135. Aiello A, Pandini G, Sarfstein R, Werner H, Manfioletti G, Vigneri R, et al. HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. Eur J Cancer (2010) 46:1919-26. doi:10.1016/j.ejca.2010.02.050.
136. Sarfstein R, Belfiore A, Werner H. Identification of insulin-like growth factor-I receptor (IGF-IR) gene promoter-binding proteins in estrogen receptor (ER)-positive and ER-depleted breast cancer cells. Cancers (Basel) (2010) 2:233-61. doi:10.3390/cancers2020233.
137. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 68:2479-88. doi:10.1158/0008-5472.CAN-07-2559.
138. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol (2007) 27:3165-75. doi:10.1128/MCB.01315-06.
139. Dupont J, Fernandez AM, Glackin CA, Helman L, Leroith D. Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor. J Biol Chem (2001) 276:26699-707. doi:10.1074/jbc. M102664200.
140. Takahashi K, Suzuki K. Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells. Int J Cancer (1993) 55:453-8. doi:10.1002/ijc.2910550322.
141. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology (2012) 56:1004-14. doi:10.1002/hep.25745.
142. Xu C, Xie D, Yu SC, Yang XJ, He LR, Yang J, et al. Beta-catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res (2013) 73:3181-9. doi:10.1158/0008-5472.CAN-12-4403.
143. Girnita L, Girnita A, Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A (2003) 100:8247-52. doi:10.1073/pnas.1431613100.
144. Chang WW, Lin RJ, Yu J, Chang WY, Fu CH, Lai A, et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res (2013) 15:R39. doi:10.1186/bcr3423.
145. Malaguarnera R, Frasca F, Garozzo A, Giani F, Pandini G, Vella V, et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab (2011) 96:766-74. doi:10.1210/jc.2010-1255.
146. Loladze AV, Stull MA, Rowzee AM, Demarco J, Lantry JH III, Rosen CJ, et al. Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. Endocrinology (2006) 147:5412-23. doi:10.1210/en.2006-0427.
147. Sun Z, Shushanov S, Leroith D, Wood TL. Decreased IGF type 1 receptor signaling in mammary epithelium during pregnancy leads to reduced proliferation, alveolar differentiation, and expression of insulin receptor substrate (IRS)-1 and IRS-2. Endocrinology (2011) 152:3233-45. doi:10.1210/en.2010-1296.
148. Cheang MC, Voduc D, Bajdik C, Leung S, Mckinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 14:1368-76. doi:10.1158/1078-0432.CCR-07-1658.
149. Cheang MC, Van De Rijn M, Nielsen TO. Gene expression profiling of breast cancer. Annu Rev Pathol (2008) 3:67-97. doi:10.1146/annurev.pathmechdis.3.121806.151505.
150. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 15:907-13. doi:10.1038/nm.2000.
151. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 12:R68. doi:10.1186/bcr2635.
152. Perou CM, Borresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 3:a003293. doi:10.1101/cshperspect.a003293.
153. Molyneux G, Geyer FC, Magnay FA, Mccarthy A, Kendrick H, Natrajan R, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 7:403-17. doi:10.1016/j.stem.2010.07.010.
154. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 27:5800-7. doi:10.1200/JCO.2009.23.6745.
155. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a Phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol (2011) 29:4541-7. doi:10.1200/JCO.2010.34.0000.
156. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, et al. A Phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer (2014) 120:2448-56. doi:10.1002/cncr.28728.
157. Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2012) 17:251-61. doi:10.1007/s10911-012-9268-y.
158. Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, et al. Randomized, Phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol (2014) 32:2059-66. doi:10.1200/JCO.2013.54.4932.
159. Lee AV, Yee D. Targeting IGF-1R: at a crossroad. Oncology (Williston Park) (2011) 25:535-6.
160. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res (2007) 67:391-7. doi:10.1158/0008-5472.CAN-06-1712.
161. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther (2010) 9:2652-64. doi:10.1158/1535-7163.MCT-10-0318.
162. Dinchuk JE, Cao C, Huang F, Reeves KA, Wang J, Myers F, et al. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807. Endocrinology (2010) 151:4123-32. doi:10.1210/en.2010-0032.
163. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 107:10791-8. doi:10.1073/pnas.0914076107.